05-666
Anti-BRCA2 Antibody, clone 5.23
clone 5.23, Upstate®, from mouse
Synonym(s):
Anti BRCC2, Anti-BROVCA2, Anti-FACD, Anti-FAD, Anti-FAD1, Anti-FANCD, Anti-FANCD1, Anti-GLM3, Anti-PNCA2, Anti-XRCC11
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
5.23, monoclonal
species reactivity
human
manufacturer/tradename
Upstate®
technique(s)
immunocytochemistry: suitable
western blot: suitable
isotype
IgG
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... BRCA2(675)
Specificity
BRCA2
Immunogen
GST fusion protein to residues 2959-3418 of human BRCA2 protein
Application
Detect BRCA2 with Anti-BRCA2 Antibody, clone 5.23 (Mouse Monoclonal Antibody), that has been shown to work in WB, ICC.
Research Category
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Research Sub Category
Cell Cycle, DNA Replication & Repair
Cell Cycle, DNA Replication & Repair
Quality
routinely evaluated by immunoblot on in HeLa nuclear extract
Target description
390kDa
Physical form
0.1M Tris-glycine, pH 7.4, 0.15M NaCl, and 0.05% sodium azide.
Format: Purified
Protein G Chromatography
Storage and Stability
Store at 2-8°C. Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at 2-8°C.
Analysis Note
Control
Positive Antigen Control: Catalog #12-309, Hela cell nuclear extract. Add an equal volume of Laemmli reducing sample buffer to 10 μL of extract and boil for 5 minutes to reduce the preparation. Load 20 μg of reduced extract per lane for minigels.
Positive Antigen Control: Catalog #12-309, Hela cell nuclear extract. Add an equal volume of Laemmli reducing sample buffer to 10 μL of extract and boil for 5 minutes to reduce the preparation. Load 20 μg of reduced extract per lane for minigels.
Other Notes
Due to license agreement restrictions, this product cannot be purchased for resale.
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
wgk_germany
WGK 1
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
BLM SUMOylation regulates ssDNA accumulation at stalled replication forks.
Ouyang, KJ; Yagle, MK; Matunis, MJ; Ellis, NA
Frontiers in Genetics null
Loredana Moro et al.
The Journal of biological chemistry, 280(23), 22482-22491 (2005-04-05)
BRCA2 is a tumor suppressor gene that when mutated confers an increased susceptibility to developing breast and prostate carcinoma. Besides its role in mediating DNA repair, new evidence suggests that BRCA2 may also play a role in suppressing cancer cell
Loredana Moro et al.
The Journal of biological chemistry, 281(31), 22100-22107 (2006-06-07)
Aberrant interaction of carcinoma cells with basement membranes (BM) is a fundamental pathophysiological process that initiates a series of events resulting in cancer cell invasion and metastasis. In this report, we describe the results of our investigations pertaining to the
Miyoung Lee et al.
Nucleic acids research, 49(10), 5588-5604 (2021-05-13)
Cancer-causing missense mutations in the 3418 amino acid BRCA2 breast and ovarian cancer suppressor protein frequently affect a short (∼340 residue) segment in its carboxyl-terminal domain (DBD). Here, we identify a shared molecular mechanism underlying their pathogenicity. Pathogenic BRCA2 missense
L Y Marmorstein et al.
Cell, 104(2), 247-257 (2001-02-24)
Germline mutations of the human BRCA2 gene confer susceptibility to breast cancer. Although the function of the BRCA2 protein remains to be determined, murine cells homozygous for BRCA2 inactivation display chromosomal aberrations. We have isolated a 2 MDa BRCA2-containing complex
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service